Zimmer Biomet (NYSE:ZBH) Cut to Hold at Wall Street Zen

Posted by George Bondi on Aug 11th, 2026

Wall Street Zen cut shares of Zimmer Biomet (NYSE:ZBH – Free Report) from a buy rating to a hold rating in a report released on Saturday.

A number of other research firms also recently issued reports on ZBH. UBS Group restated a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday. Royal Bank Of Canada raised their price target on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday. Canaccord Genuity Group set a $83.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays dropped their price target on Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $96.00 price objective on shares of Zimmer Biomet in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $104.42.

Get Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Stock Performance

Shares of ZBH opened at $97.78 on Friday. The company has a market cap of $18.65 billion, a price-to-earnings ratio of 23.79, a P/E/G ratio of 3.07 and a beta of 0.45. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The business’s fifty day simple moving average is $90.47 and its two-hundred day simple moving average is $90.23.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the company earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, June 25th. Zimmer Biomet’s payout ratio is currently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $204,000. Sivia Capital Partners LLC acquired a new position in Zimmer Biomet in the 2nd quarter worth approximately $232,000. United Bank raised its holdings in shares of Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC lifted its holdings in Zimmer Biomet by 93.6% in the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after acquiring an additional 37,116 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.